Compare CENN & ICCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CENN | ICCM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5M | 8.3M |
| IPO Year | 2017 | 2013 |
| Metric | CENN | ICCM |
|---|---|---|
| Price | $3.79 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $22.67 |
| AVG Volume (30 Days) | 11.6K | ★ 115.6K |
| Earning Date | 11-11-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $18,080,161.00 | N/A |
| Revenue This Year | N/A | $34.08 |
| Revenue Next Year | N/A | $94.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.07 | $0.13 |
| 52 Week High | $4.84 | $9.54 |
| Indicator | CENN | ICCM |
|---|---|---|
| Relative Strength Index (RSI) | 38.03 | 24.64 |
| Support Level | $3.17 | $0.22 |
| Resistance Level | $4.50 | $2.50 |
| Average True Range (ATR) | 0.26 | 0.15 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 3.23 | 0.02 |
Cenntro Inc is a designer, manufacturer, distributor, and service provider of commercial vehicles powered by either electricity or hydrogen energy sources. The company's commercial vehicles are designed to serve a variety of fleet and municipal organizations in support of city services, last-mile delivery, and other commercial applications. It has developed a series of commercial vehicle models, including Metro, Logistar, iChassis, Avantier, Teemak, Bison Motor, and Antric One. In addition, the company has introduced an open-platform, programmable all-electric iChassis platform, designed for automated and autonomous driving. Geographically, the company generates maximum revenue from vehicle sales in the Europe, and also has a presence in America, Asia, and other regions.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.